Published in Cancer Weekly, May 4th, 2004
"Despite high-dose chemotherapy and autografting, the outcome for patients with primary refractory Hodgkin's disease (HD) or multiple relapses remains unsatisfactory," hematologists in Germany explained.
In a study conducted by A. Claviez and colleagues at the University of Kiel, "[s]ix pediatric patients (median age: 16 years, range: 11-19) received reduced intensity conditioning and allogeneic peripheral blood stem-cell transplantation (PBSCT) after failure of stratified first-line chemotherapy, involved-field radiotherapy, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.